HSHiroaki Suefuji

Hiroaki Suefuji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroaki Suefuji has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multicenter study of re‐irradiation using carbon‐ions for head and neck malignancies after photon radiotherapy

    by Daiki Takahashi, Yusuke Demizu, Masashi Koto, Nobuteru Kubo, Hiroaki Suefuji, Hiroaki Ikawa, Tatsuya Ohno, Yoshiyuki Shioyama, Tomoaki Okimoto, Hiroshi Tsuji, et al.

    Purpose: The goal of this multicenter retrospective study of patients with head and neck malignancies was to evaluate the efficacy and safety of carbon‐ion (C‐ion) radiotherapy (RT) after photon RT.Methods: We enrolled 56 patients with head and neck malignancies who underwent re‐irradiation (re‐RT) using C‐ions between November 2003 and March 2019, treated previously with photon RT. The tumors at re‐RT were located in the sinonasal cavities (n = 20, 35.7%), skull base (n = 12, 21.4%), and orbit (n = 7, 12.5%). The tumors at the initial RT were located in the sinonasal cavities (n = 13, 23.2%), skull base (n = 9, 16.1%), and orbit (n = 9, 16.1%). The median period between the initial RT and re‐RT was 41 (4–568) months. The most common histology of re‐RT was squamous cell carcinoma (n = 11, 19.6%). The most commonly used protocol was 57.6 Gy (relative biological effectiveness) in 16 fractions (n = 23, 41.1%). Surgery preceded re‐RT in three patients (5.4%). One patient with malignant melanoma received concurrent chemotherapy.Results: The 2‐year local control, progression‐free survival, and overall survival rates were 66.5%, 36.9%, and 67.9%, respectively. The median follow‐up time was 28 months. Two patients (3.6%) developed grade ≥ 3 acute toxicities, and 14 (25.0%) developed grade ≥ 3 late toxicities. A single patient had confirmed grade 5 dermatitis with infection.Conclusion: Re‐RT using C‐ions for head and neck malignancies after photon RT is an effective treatment with tolerable toxicity.


  • Open Access

    Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity

    by Hiroaki Ikawa, Masashi Koto, Yusuke Demizu, Jun‐Ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Kazuhiko Hayashi, et al.

    Background: The aim of this study was to evaluate the efficacy and safety of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity in a multicenter study.Methods: Retrospective analysis of the clinicopathological features and outcomes of 76 patients with oral nonsquamous cell carcinomas with N0‐1 M0 status and were treated with carbon‐ion radiation therapy at four institutions in Japan between November 2003 and December 2014 was performed.Results: Salivary gland carcinoma, mucosal melanoma, and three other carcinomas were found in 46, 27, and 3 patients, respectively. T1‐3, T4a, and T4b disease was diagnosed in 27, 18, and 31 patients, respectively. Median follow‐up period was 31.1 months (range, 3‐118 months). Three‐year local control, progression‐free survival, and overall survival of all patients were 86.8%, 63.1%, and 78.4%, respectively. Multivariate analysis showed T classification (T4) to be a significant independent poor prognostic factor for local control. Acute grade 3 mucositis was observed in 38 patients. Grades 3 and 4 late morbidities were observed in 9 and 4 patients, respectively. No grade 5 late toxicity was observed.Conclusions: Oral nonsquamous cell carcinomas could be treated effectively, with acceptable toxicity, by carbon‐ion radiation therapy.


  • Open Access

    A retrospective multicenter study of carbon‐ion radiotherapy for external auditory canal and middle ear carcinomas

    by Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun‐Ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, et al.

    Background: We conducted a retrospective multicenter study to assess the clinical outcomes of carbon‐ion radiotherapy (CIRT) for head and neck malignancies (Japan Carbon‐Ion Radiation Oncology Study Group [J‐CROS] study: 1402 HN). We aimed to evaluate the safety and efficacy of CIRT in patients with external auditory canal (EAC) and middle ear (ME) carcinomas.Methods: Thirty‐one patients treated with CIRT at four Japanese institutions were analyzed. Fourteen patients (45.2%) had squamous cell carcinomas, 13 (41.9%) had adenoid cystic carcinomas, and four (12.9%) had other types. Nineteen (61.3%), six (19.4%), three (9.7%), and three (9.7%) patients had T4, T3, T2, and T1 disease, respectively. All patients had N0M0 status. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 33.3 mL.Results: The median follow‐up period was 18.4 months (range, 5.1‐85.6). The 1‐ and 3‐year local control and overall survival rates were 75.0% and 55.0% and 79.3% and 58.7%, respectively. Regarding grade 3 or higher toxicities, three patients (9.7%) had grade 3 dermatitis, one (3.2%) had grade 3 mucositis, and two (6.5%) had grade 3 central nervous necrosis (ie, radiation‐induced brain necrosis). No grade 4 or worse reactions were observed.Conclusion: CIRT was effective for EAC and ME carcinomas.


  • Open Access

    A multi‐institutional retrospective study of carbon‐ion radiotherapy for non‐squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon‐Ion Radiation Oncology Study Group study 1402 HN

    by Takanori Abe, Tatsuya Ohno, Masashi Koto, Yusuke Demizu, Hiroaki Suefuji, Hiroshi Tsuji, Tomoaki Okimoto, Yoshiyuki Shioyama, Jun‐Ichi Saitoh, Katsuyuki Shirai, et al.

    Background: This multi‐institutional retrospective study focused on the clinical outcome of carbon‐ion radiotherapy (C‐ion RT) for non‐squamous cell malignant tumors of the nasopharynx.Methods: The Japan Carbon‐ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non‐squamous cell malignant tumors of the nasopharynx treated with C‐ion RT at four institutions in Japan.Results: Twenty‐nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty‐six of the 43 patients (61%) had T4 tumors. The most common dose‐fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow‐up period was 30 months. The 2‐year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation.Conclusions: C‐ion RT provided good LC and OS rates with acceptable toxicity for treatment of non‐squamous cell malignant tumors of the nasopharynx.


  • Open Access

    A retrospective multicenter study of carbon‐ion radiotherapy for major salivary gland carcinomas: Subanalysis of J‐CROS 1402 HN

    by Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun‐Ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, et al.

    A retrospective multicenter study was carried out to assess the clinical outcomes of carbon‐ion radiotherapy for head and neck malignancies (Japan Carbon‐Ion Radiation Oncology Study Group [J‐CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon‐ion radiotherapy in patients with major salivary gland carcinoma. Sixty‐nine patients treated with carbon‐ion radiotherapy at four Japanese institutions were analyzed. Thirty‐three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow‐up period was 32.7 months. The 3‐year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, seven patients had grade 3 mucositis and seven had grade 3 dermatitis. Regarding late toxicities, one patient had grade 3 dysphagia and one had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon‐ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.


  • Open Access

    A case of the cirrhotic patient performed living donor liver transplantation after carbon-ion radiotherapy for hepatocellular carcinoma

    by Shingo Toyama, Yoshiyuki Shioyama, Hiroaki Suefuji, Makoto Shinoto, Keiji Matsumoto, Kotaro Terashima, Masaaki Hidaka, Susumu Eguchi, Kuniko Abe, Hiroyuki Irie, et al.

    The patient was a 50-year-old female with an initial diagnosis of a single hepatocellular carcinoma in liver cirrhosis. The tumor was located in the posterior liver segment (S7) and measured 5 cm with a rapid growth rate and portal invasion. The pre-treatment Child-Pugh (C-P) was grade A (six points). The total prescribed dose of carbon-ion radiotherapy (C-ion RT) was 60 Gy (relative biological effectiveness) given in 4 fractions. Thereafter, tumor shrinkage and rapid decrease of the serum alpha-fetoprotein level were observed. At 1-year follow-up a new lesion was diagnosed in the left lobe and the underlying liver failure had worsened to C-P grade B (eight points). Thus, she was recommended to undergo living-donor liver transplantation (LDLT). The postoperative course was uneventful. At pathological examination, no viable tumor cells in the region treated with C-ion RT were detected. At the time of the last follow-up, the patient was in overall good general condition with no signs of tumor recurrence.


  • Open Access

    A retrospective multicenter study of carbon-ion radiotherapy for the head and neck cancer except sarcoma(J-CROS1402 HN)

    by Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Hiroaki Suefuji, Hiroshi Tsuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Hiroaki Ikawa, Kenji Nemoto, et al.

    総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。


  • Carbon-ion Radiotherapy for Lung Cancer: Current Status and Future Directions

    by Yoshiyuki Shioyama, Hiroaki Suefuji, Makoto Shinoto, Kotarou Terashima, Shingo Toyama

    体幹部定位放射線治療(SBRT)や強度変調放射線治療(IMRT)に代表される線量集中性を向上させた高精度エックス線治療が急速に普及し,肺癌領域においても,I期肺癌に対する高線量局所照射の有用性が確認されるとともに,局所進行期肺癌においては心毒性などの低減に有効な可能性が示唆されている.現在,さらなる治療効果の向上を目指した線量増加などの治療法開発が進められている.しかし一方で,放射線治療の対象は,心肺予備能の低い患者や高齢者を対象とすることが多く,肺臓炎,心毒性などの有害事象には十分留意する必要もあるが,局所進行期肺癌に対する第III相比較試験の結果,線量増加は有害事象も避けられず,生存率改善に寄与しないことが判明するなど,エックス線治療の限界もうかがわせる.陽子線や炭素イオン線を用いた荷電粒子線治療は,本格的な臨床応用,普及の段階に入り,さらなる有害事象の軽減ならびに治療効果向上を可能とする新たな放射線治療として期待されている.荷電粒子線の最大の特徴は,ある一定の深さで高線量域(Bragg peak:ブラッグ・ピーク)を形成したうえで止まるという特徴を有し,このピークを腫瘍の位置や大きさに合わせて調節することで標的に集中した高線量領域を形成できることである.そのため,粒子線治療では少ない方向からの照射によって癌病巣へ線量を集中することができ,中低線量域の拡がりを最小限に抑えることが可能となり,肺臓炎や心毒性などの有害事象リスクの軽減に寄与する.また,炭素イオン線においては殺細胞効果が高く,低酸素状態や細胞周期などの影響を受けにくいという生物学的特徴もある.このような粒子線治療の理論的有用性は,単施設による検討ではあるものの,数々の臨床研究によって裏づけられてきた.現在は,多施設共同臨床研究も精力的に行われており,臨床的有用性に関するエビデンスが今後さらに明確となることが期待されている.

  • Local effect and gastrointestinal toxicity for carbon-ion radiotherapy in patients with unresectable locally advanced pancreatic cancer.

    by Makoto Shinoto, Yoshiyuki Shioyama, Hiroaki Suefuji, Akira Matsunobu, Shingo Toyama, Sho Kudo

    410 Background: Carbon-ion radiotherapy (CIRT) is a unique external radiotherapy that has an excellent dose conformity and higher biological effectiveness compared to conventional radiotherapy. The sensitivity of the organs in upper abdomen has limited the radiation dose to levels that are ineffective against pancreatic cancer, which has extreme radioresisnatnce. We investigated effectiveness and gastrointestinal (GI) toxicity of CIRT. Methods: From April 2014 to June 2015, 41 patients with pancreatic cancer were treated with definitive CIRT. 26 patients who were confirmed as unresectable locally advanced pancreatic cancer pathologically and by imaging techniques were included in this retrospective analysis. 15 patients were excluded because of resectable disease (n = 3), borderline disease (n = 4), no cell evidence (n = 11). CIRT was performed with 55.2 Gy (RBE) at 12 fractions. The maximal absolute dose with covered 2cm3 of the organ (D2) was restricted under 46 Gy (RBE). All patients were followed up using CT, FDG-PET and upper gastrointestinal endoscopy at least every six months. Anti-tumor effect was evaluated using CT and FDG-PET according to RECIST. If FDG accumulation was negative or equal to normal pancreatic tissue after CIRT, it was defined CR even no decreasing in seize on CT. GI toxicity was evaluated using CTCAE. Results: Tumor location were head in 7, head-body in 2, body-tail in 16. Median tumor size was 35mm (range 21-50). In all patients, sequential and/or concurrent chemotherapy was performed. The median follow-up period was 7.7 months. Local effect using CT criteria was CR in 0, PR in 2, SD in 22, and PD in 2. The evaluation adding FDG-PET criteria was CR in 12, PR in 4, SD in 8, and PD in 2. Two patients who were SD by CT and CR by FDG-PET performed tumor resection and were revealed pCR. The actual incidence of gastric ulcer/bleeding was 15% (n = 4). Only one patient (4%) received blood transfusion because of grade 3 gastric ulcer. The other patients experienced grade 1/2 gastric ulcer. There was no duodenal ulcer. Conclusions: CIRT were effective and well tolerated under the restriction of D2 < 46 Gy (RBE). FDG-PET was useful for the evaluation of local effect after CIRT.

  • A dosimetric analysis of acute gastrointestinal toxicity in locally advanced pancreatic cancer patients treated with carbon-ion radiotherapy

    by Makoto Shinoto, Yoshiyuki Shioyama, Hiroaki Suefuji, Akira Matsunobu, Shingo Toyama, Takeshi Himukai, Kei Okamoto, Sho Kudo